Cancer Blood Test Setback: What It Means for the Future of Early Detection A recent study has cast a shadow over the promise of early cancer detection through blood tests. Grail’s Galleri test, a leading contender in this emerging field, failed to meet its primary goal in a large-scale trial with the UK’s National Health … Read more
Alzheimer’s Drug Development: A Recent Wave of Investment and Innovation Despite the recent approval of two amyloid-targeting therapies for Alzheimer’s disease, investors are continuing to bet on new approaches to tackling the devastating condition. Korsana Biosciences, a newly launched company, has secured $175 million in funding to advance its own amyloid-clearing treatment, KRSA-028. The Persistent … Read more
Psilocybin Therapy: A New Dawn for Treatment-Resistant Depression? The landscape of mental health treatment is undergoing a significant shift, with psilocybin emerging as a potential breakthrough for individuals battling treatment-resistant depression (TRD). Compass Pathways recently released promising Phase 3 trial results for COMP360, their investigational psilocybin treatment, potentially paving the way for the second psychedelic-assisted … Read more
Ocular Therapeutix’s Axpaxli: A Potential Shift in Wet AMD Treatment? The treatment landscape for wet age-related macular degeneration (AMD) may be on the cusp of change. Ocular Therapeutix announced positive results from a late-stage clinical trial of its experimental drug, Axpaxli, demonstrating superior vision maintenance compared to aflibercept (Eylea) in patients with this common cause … Read more
FDA Rejection of Disc Medicine’s Bitopertin: A Turning Point for Fast-Tracked Drug Reviews? The Food and Drug Administration (FDA) on Friday rejected bitopertin, a therapy developed by Disc Medicine for the treatment of porphyria, a rare blood disorder causing extreme sensitivity to sunlight. This decision marks the first rejection under FDA Commissioner Marty Makary’s new … Read more
Why Endophytic Chaetomium Is the Next Substantial Thing in Natural Product Discovery Researchers are increasingly turning to endophytic fungi as a treasure chest of bioactive chemicals. Among them, the genus Chaetomium stands out for its diverse secondary metabolites – from indole alkaloids to chaetoglobosins – that demonstrate promise in medicine, agriculture and industry. Key Discoveries … Read more
FDA’s Flu Shot Rejection: A Turning Point for Biotech? The Food and Drug Administration’s (FDA) decision to decline review of Moderna’s mRNA flu vaccine has sent ripples of concern throughout the biotechnology industry. Experts are questioning whether this move signals a broader shift in regulatory approaches, particularly under the current administration. Shifting Regulatory Landscape The … Read more
FDA’s Shocking Rejection of Moderna’s Flu Vaccine: A Turning Point for mRNA Technology? The Food and Drug Administration’s (FDA) decision to refuse review of Moderna’s mRNA-based flu vaccine application has sent shockwaves through the pharmaceutical industry. Moderna President Stephen Hoge described the move as “completely shocking,” raising questions about the future of mRNA vaccine development … Read more
Unlocking the Body’s Inner Clock: How New Discoveries in Circadian Rhythms Could Revolutionize Health and Biotechnology Our 24-hour biological cycles, known as circadian rhythms, are fundamental to health and well-being. Disruptions to these rhythms – from jet lag to shift work – can have significant consequences. Now, scientists at the University of California San Diego … Read more
Oregon Primate Center Faces Potential Shift to Sanctuary: A Sign of Changing Times in Biomedical Research The Oregon Health & Science University (OHSU) board of directors has authorized negotiations with the National Institutes of Health (NIH) that could dramatically reshape the future of the Oregon National Primate Research Center (ONPRC). The potential outcome? A transition … Read more